Precision medicine is poised to transform healthcare, with biobanks being identified as a key enabler to bring it to fruition by 2030 by putting new, extended datasets at the disposal of pharmaceutical researchers and healthcare professionals. — by Marilyn Matz
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.
TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.
